Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
Can Urol Assoc J. 2019 Jul 23;:
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).
Can Urol Assoc J. 2019 Jun 25;:
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.
Eur Urol Oncol. 2019 Jul 12;:
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
Eur Urol. 2019 Jul 11;:
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Eur Urol Oncol. 2019 May;2(3):248-256
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.
Oncotarget. 2019 Apr 26;10(31):2947-2958
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.
Can Urol Assoc J. 2019 Apr 26;:
Curr Oncol. 2019 Apr;26(2):73-79
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Oncologist. 2019 Apr 05;:
Can Urol Assoc J. 2019 Jan 31;: